Azithromycin versus comparative therapy for the treatment of community acquired pneumonia

International Journal of Antimicrobial Agents

Volumn 24, Issue 2, 2004, Pages 181-184

  Rahav, Galia ^a,c   Fidel, Joseph ^b   Gibor, Yair ^b   Shapiro, Mervyn ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b Kupat Holim Klalit   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Azithromycin; Community acquired pneumonia

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFACLOR; CEFUROXIME; DOXYCYCLINE; ERYTHROMYCIN; ROXITHROMYCIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; FUNCTIONAL ASSESSMENT; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; TREATMENT OUTCOME;

EID: 3342924263     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2004.01.011     Document Type: Article

References (22)

1. Bartlett J.G., Breiman R.F., Mandell L.A., File T.M. Jr. Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis. 26:1998;811-838
2. Mandell L.A. Community-acquired pneumonia: etiology, epidemiology, and treatment. Chest. 108(Suppl.):1995;35S-42S
3. Marrie T.J. Community-acquired pneumonia: epidemiology, etiology, and treatment. Infect Dis Clin North Am. 2:1998;723-740
4. File T.M. Jr., Tan J.S. Incidence, etiologic pathogens, and diagnostic testing of community-acquired pneumonia. Curr Opin Pulm Med. 3:1997;89-97
5. Reimer L.G., Carroll K.C. Role of the microbiology laboratory in the diagnosis of lower respiratory tract infections. Clin Infect Dis. 26:1998;742-748
6. Niederman M.S., Bass J.B. Jr., Campbell G.D., et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis. 148:1993;418-426
7. Mandell L.A., Marrie T.J., Grossman R.F., Chow A.W., Hyland R.H. Canadian Infectious Disease Society. Canadian Thoracic Society. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis. 31:2000;383-426
8. Bartlett J.G., Dowell S.F., Mandell L.A., et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 31:2000;347-382
9. Lalak N.J., Morris D.L. Azithromycin clinical pharmacokinetics. Clin Pharmacokinet. 25:1993;370-374
10. Schonwald S., Skerk V., Petricevic I., et al. Comparison of three day and five day courses of azithromycin in the treatment of atypical pneumonia. Eur J Clin Microbiol Infect Dis. 10:1991;877-880
11. Schonwald S., Barsic B., Klinar I., Gunjaca M. Three day azithromycin compared with ten day roxithromycin treatment of atypical pneumonia. Scand J Infect Dis. 26:1994;706-710
12. Rizzato G., Montemurro L., Fraioli P., et al. Efficacy of a three days course of azithromycin in moderately severe community acquired pneumonia. Eur Respir J. 8:1995;398-402
13. Schonwald S., Gunjaca M., Kolacny-Babic L., Car V., Gosev M. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J Antimicrob Chemother. 25S:1990;123-126
14. Kinasewitz G., Wood R.G. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. Eur J Clin Microbiol Infect Dis. 10:1991;872-877
15. O'Doherty B, Muller O, the Azithromycin Study Group. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1998;17:828-33.
16. Bohte R., van't Wout J.W., Lobatto S., et al. Efficacy and safety of azithromycin in community acquired pneumonia. Eur J Clin Microbiol Infect Dis. 14:1995;182-187
17. Harris J.A., Kolokathis A., Campbell M., Cassell G.H., Hammerschlag M.R. Safety and efficacy of azithromycin in the treatment of community acquired pneumonia in children. Pediatr Infect Dis J. 17:1998;865-871
18. Wubbel L., Muniz L., Ahmed A., et al. Etiology and treatment of community-acquired pneumonia in ambulatory children. Pediatr Infect Dis J. 18:1999;98-104
19. Roord J.J., Wolf B.H., Gossens M.M., Kimpen J.L. Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin and a 10-day course of erythromycin in children with community-acquired acute lower respiratory tract infections. Antimicrob Agents Chemother. 40:1996;2765-2768
20. Aprim, Brion JP, Sedallian A, et al. Azithromycin versus josamycin: treatment of 89 cases of acute pneumonia. Pathol Biol 1990;38:521-5.
21. SAS procedures guide for personal computers. Version 6. Cary. North Carolina: SAS Institute; 1985.
22. Contopoulos-Ioannidis D.G., Ioannidis J.P.A., Chew P., Lau J. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J Antimicrob Chemother. 48:2001;691-703